Related Experiment Videos
Immunologic approaches to the treatment of prostate cancer
D T Harris1, G R Matyas, L G Gomella
1Thomas Jefferson University, Philadelphia, PA, USA.
Abstract:
The presence of several organ-specific molecules that could serve as immunogens or targets of an immune attack, the nonessential nature of the prostate gland, the substantial failure rate after treatment of the primary tumor, and the lack of effective chemotherapy for metastatic disease make prostate cancer an ideal candidate for immunotherapy. This report reviews the current status of two novel approaches to the treatment of prostate cancer. The first is an effort to induce antitumor immunity by enriching the cytokine environment within the primary cancer by intraprostatic injection of Leukocyte Interleukin (Cel-Sci Corp, Vienna, VA), a mixture of natural cytokines that includes interleukin-1 beta (IL-1beta), IL-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon gamma (IFN-gamma), and tumor necrosis factor alpha (TNF-alpha). The second approach uses OncoVax-P (Jenner Biotherapies, Inc, San Ramon, CA), a vaccine consisting of liposome-encapsulated recombinant prostate-specific antigen (PSA) and lipid A. When administered as an emulsion or in association with bacillus Calmette-Guérin (BCG)/cyclophosphamide or GM-CSF with or without IL-2/cyclophosphamide, immunologic tolerance is broken as evidenced by the generation of humoral and cellular immunity. Both of these approaches have been shown to be feasible and safe, and are now being tested in patients with less advanced disease to determine if manipulation of the immune system can favorably influence clinical outcome.
Insights
Novel immunotherapies for prostate cancer, including cytokine injections and a prostate-specific antigen vaccine, are being investigated. These treatments aim to stimulate the immune system against cancer, showing feasibility and safety in early trials.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Prostate cancer presents unique opportunities for immunotherapy due to organ-specific antigens and treatment limitations.
- Existing treatments for advanced prostate cancer have substantial failure rates, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review the current status of two innovative immunotherapy approaches for prostate cancer.
- To assess the feasibility, safety, and potential clinical impact of these novel treatments.
Main Methods:
- Intraprostatic injection of Leukocyte Interleukin, a natural cytokine mixture, to enhance the local antitumor immune environment.
- Administration of OncoVax-P, a vaccine comprising liposome-encapsulated prostate-specific antigen (PSA) and lipid A, with various immune-stimulating agents.
Main Results:
- Both Leukocyte Interleukin and OncoVax-P have demonstrated feasibility and safety in preliminary studies.
- OncoVax-P administration, particularly with adjuvants, has shown the ability to break immunologic tolerance and generate humoral and cellular immunity.
Conclusions:
- Immunotherapy represents a promising avenue for prostate cancer treatment, leveraging the immune system to target cancer cells.
- Ongoing clinical trials are evaluating the efficacy of these immunotherapies in patients with less advanced disease to determine their impact on clinical outcomes.